araag2/HINT huggingface dataset:
Clinical trial NCT00442780 (phase 2, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: biib014, placebo
SMILES: CC1=CC(CN2N=NC3=C(N=C(N)N=C23)C2=CC=CO2)=CC=C1N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must give written informed consent and any authorizations required by local law.

          -  Must carry a diagnosis of idiopathic Parkinson's Disease(PD), without any other known
             or suspected cause of parkinsonism, according to the UK Parkinson's Disease Society
             Brain Bank Clinical Diagnostic Criteria. Initial diagnosis of PD must have been made
             within the 5 years prior to Screening with at least two or more of the following
             cardinal signs being present: bradykinesia, resting tremor, rigidity, and postural
             instability.

          -  Must be modified Hoehn & Yahr Stage 1 to 2.5 (inclusive).

          -  Must have a baseline UPDRS (Part III) motor score of at least 10.

          -  Subjects may be receiving an anticholinergic agent and/or MAO-B inhibitor (if they
             have been on a stable dose of that medication for at least 4 weeks prior to study
             entry) but must not be receiving any other PD medication.

        Exclusion Criteria:

          -  A Mini Mental State Examination (MMSE) score <26.

          -  History or clinical features consistent with an atypical parkinsonian syndrome.

          -  Any significant non-PD central nervous system disorder.

          -  Any significant AXIS I psychiatric disease as defined by the Diagnostic and
             Statistical Manual of Mental Disorders.

          -  History of cognitive or neuropsychiatric conditions.

          -  History of surgical intervention for PD.

          -  History of L-DOPA-induced motor or non-motor complication.

          -  History of malignancy.

          -  History of severe allergic or anaphylactic reactions to any drug.

          -  Clinically significant renal dysfunction.

          -  HbA1c >7.0%.

          -  Clinically significant baseline ECG.

          -  Orthostatic hypotension.

          -  Treatment with L-DOPA/carbidopa or L-DOPA/benserazide for more than 6 cumulative
             months at anytime since subject's initial PD diagnosis.
Clinical trial NCT00321711 (phase 2, status: completed)
Conditions: mds, myelodysplastic syndromes, thrombocytopenia
ICD codes: D46.9, D46.C, D46.Z, D69.6, D69.49, D69.59, P61.0, D75.82, D69.42, O36.8211
Drugs: placebo, azacitidine, decitabine
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, CN(C)\N=N\C1=C(N=CN1)C(N)=O
Eligibility criteria:

        Inclusion Criteria: - Diagnosis of MDS by bone marrow biopsy based on the World Health
        Organization (WHO) classification - Low, Intermediate-1 or Intermediate-2 risk category MDS
        using the IPSS (International Prognostic Scoring System) - Planned to receive either
        azacytidine 75 mg/m2 by subcutaneous administration each day for 7 days or decitabine 20
        mg/m2 by intravenous administration each day for 5 days for at least 4 cycles Exclusion
        Criteria:

          -  Prior exposure to >3 cycles hypomethylating agents

          -  Prior history of leukemia or aplastic anemia

          -  Prior history of bone marrow transplantation

          -  Prior malignancy (other than in situ cervical cancer or basal cell cancer of the skin)
             unless treated with curative intent and without evidence of disease for ³ 3 years
             before randomization

          -  Active or uncontrolled infections

          -  Unstable angina, congestive heart failure [NYHA (New York Heart Association) > class
             II], uncontrolled hypertension [diastolic > 100 mmHg], uncontrolled cardiac
             arrhythmia, or recent (within 1 year) myocardial infarction

          -  History of arterial thrombosis ( eg, stroke or transient ischemic attack) in the past
             year

          -  History of venous thrombosis that currently requires anti-coagulation therapy

          -  Received IL-11 within 4 weeks of screening

          -  Less than 4 weeks since receipt of any therapeutic drug or device that is not FDA
             approved for any indication

          -  Have previously received any other thrombopoietic growth factor
Clinical trial NCT00448292 (phase 2, status: completed)
Conditions: major depressive disorder (mdd)
ICD codes: F25.1, F32.89, F33.8, F33.0, F33.1, F33.9, F32.0
Drugs: prx-00023, placebo for prx-00023
SMILES: CC(=O)NC1=CC=CC(=C1)N1CCN(CCCCNS(=O)(=O)CC2CCCCC2)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Diagnosis of major depressive disorder

        Key Exclusion Criteria:

          -  Females who are pregnant or nursing

          -  Electroconvulsive therapy within previous year

          -  Type 1 diabetes or uncontrolled type 2 diabetes

          -  HIV, Hepatitis B or Hepatitis C

          -  Use of illegal drugs, history of drug abuse, and/or alcohol dependence

          -  Clinically significant abnormal lab results

        Other protocol-defined eligibility criteria may apply.
Clinical trial NCT00663936 (phase 2, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: t-817ma, placebo
SMILES: OC1CN(CCCOCCC2=CC3=C(SC=C3)C=C2)C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female (post-menopausal or surgically sterile)

          2. Patients with Mild to moderate Alzheimer's disease who are receiving Donepezil.

          3. Age 50 to 90 inclusive

          4. Patients must be living in the community

          5. Patients must have an eligible informant or study partner (caregiver)

          6. Patients and eligible informant or study partner (caregiver) must be able to read and
             understand English.

          7. Informed consent obtained from both the patient and the caregiver etc (According to
             the protocol)

        Exclusion Criteria:

          1. Patients with clinically significant cardiac, hepatic or renal impairment

          2. Patient have a dementia not of the Alzheimer's type etc (According to the protocol)

          3. Patients who are taking any drug other than donepezil for Alzheimer's disease,
             including rivastigmine (Exelon®), galantamine (Razadyne®), memantine (Namenda™) or
             tacrine (Cognex®) taken within twelve (12) weeks of the Baseline Visit (Visit 2).
Clinical trial NCT00736489 (phase 2, status: completed)
Conditions: asthma, airway obstruction
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: azd3199, formoterol, placebo
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Asthmatic patients with pre-bronchodilatory FEV1 above 60% of predicted normal and
             above 1.5 liters.

          -  Men and post-menopausal women above 18 years of age.

          -  Reversible airway obstruction in response to classical beta2-agonist (salbutamol)

          -  Non/ex-smokers

        Exclusion Criteria:

          -  Any clinically significant disease or disorder other than asthma

          -  Any clinically relevant abnormal findings at screening examinations

          -  Treatment with systemic glucocorticosteroids within the past 30 days

          -  Inhaled corticosteroid use if dosing is not kept constant
Clinical trial NCT01365130 (phase 2, status: terminated)
Conditions: esophageal, gastrooesophageal cancer, gastric cancer
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: jevtana
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C
Reason stopped: 
    as of 12/12/12 study closed to enrollment because study was determined to be ineffective.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients are required to have histologically or pathologically confirmed metastatic
             gastric or esophageal adenocarcinoma.

          -  Patients must demonstrate relapse or progression after at least one prior line of
             chemotherapy for metastatic disease.

          -  Patients must have measurable disease by CT scan or MRI

          -  Absolute neutrophil count ≥ 1,500/uL, platelet ≥ 100,000/uL and Hgb > 8.0 g/dl.

          -  Total bilirubin ≤ upper institutional limit of normal (ULN), and AST or ALT ≤ 3x ULN;
             if liver metastases then AST or ALT < 5x ULN

          -  Peripheral neuropathy must be ≤ Grade 1

          -  Creatinine < 2 x ULN

          -  ECOG performance status 0 to 2

          -  Minimum life expectancy of 12 weeks.

          -  Age older than 18 years.

          -  Voluntary, signed written informed consent.

          -  Women of childbearing potential must have a negative pregnancy test Men and women of
             childbearing potential must be willing to consent to using effective contraception
             while on treatment and for at least 3 months thereafter.

        Exclusion Criteria:

          -  History of severe hypersensitivity reaction to Cabazitaxel or other drugs formulated
             with polysorbate 80.

          -  Patients with known, untreated brain metastasis

          -  Any uncontrolled severe, intercurrent illness.

          -  Women who are breast-feeding.

          -  Patients who have undergone major surgery, chemotherapy, or radiotherapy within the
             last 3 weeks.

          -  Patients on concurrent anticancer therapy
Clinical trial NCT00534625 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: zileuton, placebo, zileuton
SMILES: CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female patients 12 years of age or older

          2. Diagnosis of asthma by current ATS guidelines

          3. FEV1 of 4-80%.

          4. Reversibility of at least 13% after bronchodilator treatment

          5. Must be willing to with hold SABA for 6 hours and ICS for 24 hours prior to treatment.

          6. Informed consent

        Exclusion Criteria:

          1. Females of child bearing potential unless using birth control

          2. Uncontrolled systemic disease

          3. Known hypersensitivity to zileuton or components of zileuton injection.

          4. Upper or lower respiratory tract infection within the last 2 weeks

          5. Admission to hospital or ER visit for asthma exacerbation within the last 3 months

          6. Course of oral or parenteral steroids within the last 3 months

          7. Current smoker or H/O > 15 pack years

          8. Creatinine > 1.5 x ULN

          9. ALT > 3 x ULN

         10. BP < 100 (systolic)

         11. H/O HIV

         12. H/O alcohol or drug abuse

         13. Patients taking Xolair, theophylline, montelukast, zafirlukast, nedocromil, cromolyn
             sodium, Zyflo (within the past 7 days), warfarin, propranolol, inhaled
             anti-cholinergics, or LABA.

         14. Pregnant or breast feeding females

         15. Current participation or participation in an experimental drug study within 30 days.
Clinical trial NCT01022112 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ta-7284-low, ta-7284-low-middle, ta-7284-high-middle, ta-7284-high, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Aged from 20 to 80 years inclusive on the day of informed consent;

          -  Patients who was diagnosed with type 2 diabetes mellitus at least 3 months before the
             start of the run-in period;

          -  Patients with HbA1c of ≥6.5% and ≤9.5% (according to the Japan Diabetic Society [JDS]
             criteria) on the start day of the run-in period;

        Exclusion Criteria:

          -  Type I diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, or
             secondary diabetes mellitus (acromegaly, Cushing's syndrome, etc.);

          -  Past or current history of severe diabetic complications (proliferative diabetic
             retinopathy, stage III or later stage overt nephropathy, diabetic ketoacidosis, or
             serious diabetic neuropathy);

          -  Fasting blood glucose of >270 mg/dL on the start day of the run-in period or at Week 2
             of the run-in period;

          -  eGFR of <60 mL/min/1.73 m2 on the start day of the run-in period;

          -  Systolic blood pressure of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg on the
             start or end day of the run-in period;

          -  History of myocardial infarction, unstable angina, or cerebrovascular disorder within
             3 months before the start of the run-in period;

          -  Concurrent serious (e.g., requiring inpatient hospitalization or surgical
             intervention) renal or hepatic disease;

          -  Past or current history of malignant tumor; however, this criterion shall not apply to
             those who have been free of relapse for at least 5 years even with a history of
             malignant tumor.

          -  Past or current history of drug hypersensitivity such as shock and anaphylactoid
             symptoms;

          -  Pregnant women, lactating mothers, or women of childbearing potential;

          -  Any condition that subjects are assessed to be ineligible by the investigator (sub
             investigator).
Clinical trial NCT00250718 (phase 2, status: terminated)
Conditions: non-hodgkin's lymphoma, cancer
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: vincristine, vp-16, rituximab, dexamethasone, levofloxacin
SMILES: CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, [H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O
Reason stopped: 
    low rate of accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  All patients, 18 years of age or older, with Hodgkin's lymphoma, Non-Hodgkin lymphoma
             (NHL), multiple myeloma (MM), or chronic lymphocytic leukemia (CLL) are eligible.

          -  Patients must have a life expectancy of at least 12 weeks.

          -  Patients must have a Zubrod performance status of 0-2.

          -  Patients must sign an informed consent.

          -  Patients should have adequate bone marrow function defined by an absolute peripheral
             granulocyte count of > 1,000 or cells/mm3 and platelet count >50,000/mm3 and absence
             of a regular red blood cell or platelet transfusion requirement.

          -  Patients should have adequate hepatic function with a total bilirubin < 2 mg/dl and
             SGOT or SGPT < two times the upper limit of normal, and adequate renal function as
             defined by a serum creatinine < 2.0 x upper limit of normal.

          -  Patients must have received at least two previous chemotherapy regimens for their
             disease.

          -  Patients must have measurable disease (NHL) or evaluable disease (MM, CLL).

        Exclusion Criteria:

          -  Patients with symptomatic brain metastases are excluded from this study.

          -  Pregnant women or nursing mothers are not eligible for this trial. Patients of child
             bearing potential must use adequate contraception.

          -  Patients may receive no other concurrent chemotherapy or radiation therapy during this
             trial.

          -  Patients with severe medical problems such as uncontrolled diabetes mellitus or
             cardiovascular disease or active infections are not eligible for this trial.
Clinical trial NCT00255476 (phase 2, status: completed)
Conditions: squamous cell cancer, cancer of head and neck
ICD codes: C96.20, C96.29, D47.09
Drugs: gefitinib, cisplatin, 5-flourouracil
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, FC1=CNC(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of written informed consent

          -  Patients with histologically proven primary SCCHN

          -  Aged 18 or over

        Exclusion Criteria:

          -  Patients eligible for surgery with curative intent

          -  Other co-existing malignancies diagnosed within the last 5 years with the exception of
             basal cell carcinoma or cervical cancer in situ

          -  Exclude UCNT
Clinical trial NCT00466921 (phase 2, status: completed)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: lenalidomide
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed mycosis fungoides/Sézary syndrome

               -  Stage IA-IVB disease

          -  Must have failed ≥ 1 prior topical treatment, including any of the following:

               -  Steroids

               -  Nitrogen mustard

               -  Retinoids

               -  Phototherapy

               -  Photochemotherapy

               -  Radiotherapy

               -  Total skin electron beam

          -  Measurable disease with ≥ 1 indicator lesion designated prior to study entry

               -  Erythrodermic patients are eligible

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  WBC ≥ 3,000/mm³

          -  ANC ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Creatinine ≤ 2.0 mg/dL

          -  Bilirubin ≤ 2.2 mg/dL

          -  AST and ALT ≤ 2 times upper limit of normal

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile women must use effective double-method contraception for ≥ 4 weeks before,
             during, and for ≥ 4 weeks after completion of study therapy

          -  Fertile men must use effective contraception during and for ≥ 4 weeks after completion
             of study therapy

          -  No other malignancy within the past 5 years except treated squamous cell and basal
             cell carcinoma of the skin, carcinoma in situ of the cervix, or surgically removed
             melanoma in situ of the skin (stage 0), with histologically confirmed free margins of
             excision and no current evidence of disease

          -  No acute infection requiring systemic treatment

          -  No known allergic reaction or hypersensitivity to thalidomide

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 4 weeks since prior topical therapy, systemic chemotherapy, or biological
             therapy

          -  No prior stem cell transplantation

          -  No other concurrent systemic antipsoriatic or anticancer therapies, including
             radiotherapy, thalidomide, or other investigational agents

          -  No other concurrent topical agents except emollients
Clinical trial NCT00568776 (phase 2, status: completed)
Conditions: alzheimer disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: placebo control, elnd005, elnd005, elnd005
SMILES: CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1, O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O, O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O, O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of probable AD

          -  Age 50 to 85 years, inclusive

          -  Mini-Mental Status Exam (MMSE) score of 16-26, inclusive

          -  Brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD

          -  Fluency in English, French, or Spanish

          -  Stable doses of medications (cholinesterase inhibitors and memantine allowed)

          -  Caregiver is able to attend all study visits

        Exclusion Criteria:

          -  Significant neurological disease other than AD

          -  Major psychiatric disorder

          -  Significant medical illness

          -  History of stroke or seizure

          -  History of a heart attack within the last 2 years

          -  Prior treatment with certain experimental medicines

          -  Presence of pacemakers or foreign metal objects in the eyes, skin, or body that would
             prevent patient from having MRI scan
Clinical trial NCT01756482 (phase 2, status: completed)
Conditions: respiratory syncytial virus infections
ICD codes: R09.2, A15.7, A15.8, A15.9, J98.9, R06.03, J12.1
Drugs: gs-5806, placebo
SMILES: CC1=CN2N=C(C=C2N=C1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)C1=CC(Cl)=CC=C1NS(C)(=O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy male or female

          -  Between 18 to 45 years old

          -  Body Mass Index of 18 to 33 kg/m2

        Exclusion Criteria:

          -  Acute or chronic medical illness

          -  Positive for Human Immunodeficiency Virus, Hepatitis B or C

          -  Nose or nasopharynx abnormalities

          -  Abnormal lung function
Clinical trial NCT00174226 (phase 2, status: completed)
Conditions: attention deficit disorder with hyperactivity
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: atomoxetine, buspirone
SMILES: CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Adults with ADHD

        Exclusion Criteria:

          -  Other Axis I Psychiatric Disorders